Simple Summary Positron emission tomography (PET) imaging is increasingly used to
supplement MRI in the management of patient with brain tumors. In this article, we provide a …

PET with amino acid tracers provides additional insight beyond MR imaging into the biology
of gliomas that can be used for initial diagnosis, delineation of tumor margins, planning of …

For decades, several amino acid PET tracers have been used to optimize diagnostics in
patients with brain tumors. In clinical routine, the most important clinical indications for amino …

Simple Summary PET using radiolabelled amino acids has become an essential tool for
diagnosing brain tumours in addition to MRI. O-(2-[18F] fluoroethyl)-l-tyrosine (FET) is one of …

Conventional MRI has important limitations when assessing for progression of disease
(POD) versus treatment-related changes (TRC) in patients with malignant brain tumors. We …

Purpose Both amino acid positron emission tomography (PET) and magnetic resonance
imaging (MRI) blood volume (BV) measurements are used in suspected recurrent high …

Simple Summary Reliable differentiation between true tumor progression and treatment-
related changes is a challenging situation in the management of glioma patients. Both …

Neuroimaging plays a pivotal role in the diagnosis, management, and prognostication of
brain tumors. Recently, the World Health Organization published the fifth edition of the WHO …

Simple Summary In the realm of neurology, advanced imaging tools play a crucial role as
critical endpoints in clinical trials. While magnetic resonance imaging (MRI) serves as a …

Abstract Background Diagnostic value of 3, 4-dihydroxy-6-[18F] fluoro-L-phenylalanine
([18F] FDOPA) PET in patients with suspected recurrent gliomas is recognised. We …